Pharmaxis completes Topigen acquisition as antifibrotic moves forward
This article was originally published in Scrip
Executive Summary
Pharmaxis has completed its acquisition of the private Canadian firm Topigen Pharmaceuticals in a move which expands its development portfolio in the respiratory area.